Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

pharmacogenomics 4860 > Hematology (Final Exam) > Flashcards

Hematology (Final Exam) Flashcards

1
Q

genes associated with cancer development that have normal cellular counterparts or proto-oncogenes

A

oncogenes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

genes coding for proteins that deter cancer development through regulation of cell growth and division. during cancer development, genetic events may occur that inactivate these genes

A

tumor suppressor genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

these drugs are used to treat _____
Imatinib (GLEEVEC)
Nilotinib (TASIGNA)
Bosutinib (BOSULIF)
Dasatinib (SPRYCEL)
Ponatinib (ICLUSIG)
Asciminib (SCEMBLIX)

A

chronic myelogenous leukemia (CML)
I never believed daneshtalabs pharmacology anyway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

this is used for treatment of newly diagnosed BCR/ABL-1 positive CML (Chronic phase) or treatment go BCR/ABL1-positive CML (Chronic phase, accelerated phase or blast phase) in patients resistance to interferon therapy.

A

Imatinib (GLLEVEC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

true or false: Imatinib (GLEEVEC) is effective for T315i mutation

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

this is used for treatment of newly diagnosed BCR/ABL1-positive CML (Chronic phase) or treatment of BCR/ABL1-positive CML (Chronic phase or accelerated phase) in adult patients resistant to prior tyrosine-kinase inhibitor (TKI) therapy. 30x stronger than Imiatinib due to better fit of molecule to binding site

A

Nilotinib (TASIGNA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

true or false: Nilotinib (TASIGNA) is effective for T315i mutation

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

this is used for treatment of newly diagnose BCR/ABL1-positive CML (chronic phase) or treatment of BCR/ABL1-positive CML (chronic phase, accelerated phase or blast phase) with resistance or intolerance to prior therapy (e.g. Imatinib). 30x stronger than Imatinib due to better fit of molecule to binding site

A

Bosutinib (BOSULIF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

true or false: Bosutinib (BOSULIF) is effective for T315i mutation

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

this is used for treatment of BCR/ABL1-positive CML (chronic phase, accelerated phase or blast phase) with resistance/intolerance to prior therapy (e.g. imatinib). 325x more potent than Imatinib due to MUCH better fit of molecule into binding site

A

Dasatinib (SPRYCEL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

true or false: Dasatinib (SPRYCEL) is effective for T315i mutation

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

this is used to treat CML (Chronic phase, accelerated phase or blast phase) where no other TKI therapy is indicated or treatment of T315i-positive CML (CP, AP or BP)

A

Ponatinib (ICLUSIG)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

true or false: Ponatinib (ICLUSIG) is effective for T315i mutation

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

this is used to treat BCR/ABL1-positive CML (chronic phase) previously treated with two or more TKIs or BCR/ABL1-positive CML (chronic phase) with the T315i mutation. less toxicity compared to others

A

Asciminib (SCEMBLIX)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

true or false: Asciminib (SCEMBLIX) is effective for T315i mutation

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

this group of drugs are used to treat _____________
Lenalidomide (REVLIMID)
Imatinib (GLEEVEC)

A

myelodysplastic syndrome (MDS)
*Leftover Icecream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

this is used to treat low or intermediate risk MDS associated with a deletion 5q cryogenic abnormality with or without additional cytogenetic abnormalities

A

Lenalidomide (REVLIMID)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

this is used to treat MDS associated with PDGFR gene rearrangements (FIP1L1/PDGFRA)

A

Imatinib (GLEEVEC)

19
Q

these drug are used to treat ______
Midostaurin (RYDAPT)
Gilteritinib (XOSPATA)
Ivosidenib (TIBSOVO) & Olutasidenib (REZLIDHIA)
Enasidenib (IDHIFA)
Gemtuzumab (MYLOTARG)

A

acute myeloid leukemia (AML)
*Money Glitter In & Out Equals Gems

20
Q

this is used to treat newly diagnosed AML that is FLT3 mutation positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. there are two major types of FLT3 mutations: exon 14 ITD (in-frame) and point mutations in activating loops of kinase domain

A

Midostaurin (RYDAPT)

21
Q

this is used to treat relapsed or refractory AML with an FLT3 mutation

A

Gilteritinib (XOSPATA)

22
Q

this is used to treat newly diagnosed AML with a susceptible IDH1 mutation OR relapsed or refractory AML

A

Ivosidenib (TIBSOVO) and Olutasidenib (REZLIDHIA)

23
Q

which amino acid is affected regarding Ivosidenib (TIBSOVO) & Olutasidenib (REZLIDHIA) and the IDH1 gene

A

132 amino acid

24
Q

this is used for treatment of relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2)

A

Enasidenib (IDHIFA)

25
Q

which amino acid is affected regarding Enasidenib (IDHIFA) and the IDH2 gene

A

140 and 172 amino acid

26
Q

this is used for treatment of newly diagnosed or refractory CD33-positive AML in patient 2 years and older

A

Gemtuzumab Ozogamicin (MYLOTARG)

27
Q

these drugs are used to treat _____
Arsenic Trioxide and Tretinoid

A

acute promyelocytic leukemia (APL)

28
Q

this is used to treat APL which is characterized by the t(15:17) chromosomal translocation of PML and RARA genes

A

Arsenic Trioxide (TRISENOX) & Tretinoin (VESANOID)

29
Q

this is used to treat _______
imatinib (GLEEVEC)

A

chronic eosinophilic leukemia (CEL) and aggressive systemic mastocytosis (ASM)

30
Q

this is used for treatment of CEL associated with PDGFR gene re-arragements (FIP1L1/PDGFRA)

A

Imatinib (GLEEVEC)

31
Q

this is used to treat aggressive systemic mastocytosis (ASM) WITHOUT the D816V c-KIT mutation

A

Imatinib (GLEEVEC)

32
Q

these are used for treatment of _____________
Imatinib (GLEEVEC)
Dastinib (SPRYCEL)
Ponatinib (ICLUSIG)
Blinatumomab (BLINCYTO)
Vincristine (MARQIBO)
Mercaptopurine (PURINETHOL)

A

acute lymphoblastic leukemia (ALL)
* I Don’t Party Before Viagra’s Made

33
Q

this is used to treat relapsed/refractory BCR/ABL1 positive ALL or newly diagnosed BCR/ABL1-positive ALL in combination with chemotherapy

A

Imatinib (GLEEVEC)

34
Q

this is used to treat BCR/ABL1-positive ALL with resistance or intolerance to prior therapy or newly diagnosed BCR/ABL1-positive ALL in combination with chemotherapy

A

Dasatinib (SPRYCEL)

35
Q

this is used to treat T315i-postitive BCR/ABL1-positive ALL or BCR/ABL1-positive ALL where no other TKI therapy is indicated

A

Ponatinib (ICLUSIG)

36
Q

this is used to treat BCR/ABL1-NEGATIVE relapsed or refractory B-cell precursor ALL

A

Blinatumomab (BLINCYTO)

37
Q

this is used to treat BCR/ABL1-NEGATIVE ALL in relapse or where disease has progressed following two or more anti-leukemia therapies

A

Vincristine (MARQIBO)

38
Q

this is used to treat ALL as a component of a combination maintenance therapy regimen. Used for TPMT/NUDT15
- TPMT2/3A/3C = reduced enzyme activity
- NUDT152/3 = poor metabolizers
- NUDT154/5/6 = intermediate metabolizers

A

Mercaptopurine (PURINETHOL)

39
Q

these are used to treat ______
Ibrutinib (IMBRUVICA)
Venetoclax (VENCLEXTA)

A

chronic lymphocytic leukemia (CLL)
*I.V.

40
Q

this is used to treat chronic lymphocytic leukemia (CLL) with 17p deletion

A

Ibrutinib (IMBRUVICA)

41
Q

this is used to treat chronic lymphocytic leukemia (CLL) with 17p deletion refractory to at least one prior treatment

A

Venetoclax (VENCLEXTA)

42
Q

this is used to treat CD20+ diffuse large B-cell non-Hodgkin’s lymphoma

A

Rituximab (RITUXAN)

43
Q

this is used to treat persistent or recurrent cutaneous T-cell lymphoma (CTCL) where malignant cells express the CD25 component of the IL-2 receptor

A

Denileukin Diftitox (ONTAK)

44
Q

this is used to treat CD30-expressing peripheral T-cell lymphomas (PTCL) in combination with chemotherapy

A

Brentuximab Vedotin (ADCETRIS)

pharmacogenomics 4860 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions